InvestorsHub Logo
Followers 18
Posts 1135
Boards Moderated 0
Alias Born 11/21/2017

Re: exwannabe post# 211771

Friday, 02/01/2019 3:53:08 PM

Friday, February 01, 2019 3:53:08 PM

Post# of 710056
I think crossover is an issue because sorting out progression from psuedoprogression is difficult. Say a patient progresses, so they’re placed into the crossover. But now they keep progressing. What is their PFS? What if now with that they’re in crossover, their progression is now psuedoprogression? How does the company measure that? At what point did progression stop and the psuedoprogression begin? Does psuedoprogression now count towards PFS in the crossover arm?

The PFS endpoint is complicated with psuedoprogression notes in this trial and the crossover arm. I think that’s what Les was referring to.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News